MA39983A - Dérivés de carboxamide - Google Patents
Dérivés de carboxamideInfo
- Publication number
- MA39983A MA39983A MA039983A MA39983A MA39983A MA 39983 A MA39983 A MA 39983A MA 039983 A MA039983 A MA 039983A MA 39983 A MA39983 A MA 39983A MA 39983 A MA39983 A MA 39983A
- Authority
- MA
- Morocco
- Prior art keywords
- carboxamide derivatives
- present
- relates
- compounds
- manufacture
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
La présente invention concerne un composé de formule (i) ou un sel pharmaceutiquement acceptable de celui-ci; un procédé de fabrication de composés de l'invention et leurs utilisations thérapeutiques. La présente invention concerne, en outre, une combinaison de principes pharmacologiquement actifs et une composition pharmaceutique.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14168303 | 2014-05-14 | ||
PCT/US2015/030817 WO2015175796A1 (fr) | 2014-05-14 | 2015-05-14 | Dérivés de carboxamide |
Publications (2)
Publication Number | Publication Date |
---|---|
MA39983A true MA39983A (fr) | 2017-03-22 |
MA39983B1 MA39983B1 (fr) | 2021-05-31 |
Family
ID=50735903
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA39983A MA39983B1 (fr) | 2014-05-14 | 2015-05-14 | Dérivés de carboxamide |
Country Status (38)
Country | Link |
---|---|
US (6) | US9403810B2 (fr) |
EP (1) | EP3143018B1 (fr) |
JP (1) | JP6523338B2 (fr) |
KR (2) | KR20230074827A (fr) |
CN (1) | CN106661012B (fr) |
AP (1) | AP2016009550A0 (fr) |
AR (1) | AR100440A1 (fr) |
AU (1) | AU2015259083B2 (fr) |
BR (1) | BR112016026552B1 (fr) |
CA (1) | CA2948543C (fr) |
CL (1) | CL2016002839A1 (fr) |
CR (1) | CR20160527A (fr) |
CU (1) | CU24434B1 (fr) |
CY (1) | CY1124251T1 (fr) |
DK (1) | DK3143018T3 (fr) |
EA (1) | EA030938B1 (fr) |
ES (1) | ES2874882T3 (fr) |
HR (1) | HRP20210783T1 (fr) |
HU (1) | HUE054590T2 (fr) |
IL (1) | IL248785B (fr) |
JO (1) | JO3610B1 (fr) |
LT (1) | LT3143018T (fr) |
MA (1) | MA39983B1 (fr) |
MX (1) | MX2016014939A (fr) |
MY (1) | MY186598A (fr) |
PE (1) | PE20171443A1 (fr) |
PH (1) | PH12016502246A1 (fr) |
PL (1) | PL3143018T3 (fr) |
PT (1) | PT3143018T (fr) |
RS (1) | RS61874B1 (fr) |
SG (1) | SG11201609217UA (fr) |
SI (1) | SI3143018T1 (fr) |
SV (1) | SV2016005313A (fr) |
TN (1) | TN2016000489A1 (fr) |
TW (2) | TW201946921A (fr) |
UY (1) | UY36124A (fr) |
WO (1) | WO2015175796A1 (fr) |
ZA (1) | ZA201607658B (fr) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9403810B2 (en) | 2014-05-14 | 2016-08-02 | Novartis Ag | Carboxamide derivatives |
TW201623288A (zh) | 2014-05-14 | 2016-07-01 | 諾華公司 | 甲醯胺衍生物 |
SG11202003825TA (en) * | 2017-11-01 | 2020-05-28 | Bristol Myers Squibb Co | Spirocyclic compounds as farnesoid x receptor modulators |
CN108689976B (zh) * | 2018-07-23 | 2021-12-28 | 陕西师范大学 | 5-磺基水杨酸协同二氯二茂钛催化合成4-碘代四氢吡喃衍生物的方法 |
EP4211171A2 (fr) | 2020-09-10 | 2023-07-19 | Precirix N.V. | Fragment d'anticorps contre fap |
WO2023203135A1 (fr) | 2022-04-22 | 2023-10-26 | Precirix N.V. | Anticorps radiomarqué amélioré |
WO2023213801A1 (fr) | 2022-05-02 | 2023-11-09 | Precirix N.V. | Pré-ciblage |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2655009A1 (de) | 1976-12-04 | 1978-06-15 | Hoechst Ag | Isoxazolderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende mittel |
US7354722B1 (en) | 1999-06-11 | 2008-04-08 | Signal Pharmaceuticals | Modulators of Smurf and BMP/TGFβ signaling pathways |
WO2000077168A2 (fr) * | 1999-06-11 | 2000-12-21 | The Research Foundation Of State University Of New York | ANTAGONISTES DES VOIES DE SIGNALISATION BMP ET TGF$g(b) |
EP1631260A2 (fr) | 2003-02-28 | 2006-03-08 | Transform Pharmaceuticals, Inc. | Compositions pharmaceutiques a base d'un co-cristal |
GB0312368D0 (en) | 2003-05-30 | 2003-07-02 | Univ Aston | Novel ureido- and amido-pyrazolone derivatives |
EP1667983A4 (fr) * | 2003-09-23 | 2010-07-21 | Merck Sharp & Dohme | Modulateurs pyrazole de recepteurs de glutamate metabotropiques |
US7291743B2 (en) | 2005-03-29 | 2007-11-06 | Geneblue Corporation | Isoxazole derivatives and methods of treating nitric oxide mediated diseases |
WO2008121861A2 (fr) | 2007-03-28 | 2008-10-09 | Xenon Pharmaceuticals Inc. | Composés à base de pyrazole et de pyrrole utiles dans le traitement de troubles du métabolisme du fer |
WO2009011850A2 (fr) | 2007-07-16 | 2009-01-22 | Abbott Laboratories | Nouveaux composés thérapeutiques |
US8211927B2 (en) | 2007-08-02 | 2012-07-03 | MSD, Oss B.V. | 5-phenyl-isoxazole-3-carboxamide derivatives as TRPV1 modulators |
KR101218926B1 (ko) | 2007-08-22 | 2013-01-04 | 아이알엠 엘엘씨 | 키나제 억제제로서의 5-(4-(할로알콕시)페닐)피리미딘-2-아민 화합물 및 조성물 |
EP2219646A4 (fr) * | 2007-12-21 | 2010-12-22 | Univ Rochester | Procédé permettant de modifier la durée de vie d'organismes eucaryotes |
WO2011151361A1 (fr) | 2010-06-03 | 2011-12-08 | Glaxo Group Limited | Nouveaux composés |
CN103380130B (zh) | 2011-02-18 | 2015-06-17 | 埃科特莱茵药品有限公司 | 用作为食欲素拮抗剂的新颖的吡唑和咪唑衍生物 |
TW201623288A (zh) * | 2014-05-14 | 2016-07-01 | 諾華公司 | 甲醯胺衍生物 |
US9403810B2 (en) | 2014-05-14 | 2016-08-02 | Novartis Ag | Carboxamide derivatives |
JP6663857B2 (ja) | 2014-05-14 | 2020-03-13 | ファイザー・インク | ピラゾロピリジンおよびピラゾロピリミジン |
WO2015173659A2 (fr) * | 2014-05-14 | 2015-11-19 | Novartis Ag | Dérivés de carboxamide |
-
2015
- 2015-05-13 US US14/711,684 patent/US9403810B2/en active Active
- 2015-05-13 TW TW108119419A patent/TW201946921A/zh unknown
- 2015-05-13 TW TW104115287A patent/TWI714528B/zh active
- 2015-05-14 RS RS20210629A patent/RS61874B1/sr unknown
- 2015-05-14 KR KR1020237016401A patent/KR20230074827A/ko not_active Application Discontinuation
- 2015-05-14 JP JP2016567570A patent/JP6523338B2/ja active Active
- 2015-05-14 WO PCT/US2015/030817 patent/WO2015175796A1/fr active Application Filing
- 2015-05-14 UY UY0001036124A patent/UY36124A/es active IP Right Grant
- 2015-05-14 AP AP2016009550A patent/AP2016009550A0/en unknown
- 2015-05-14 CA CA2948543A patent/CA2948543C/fr active Active
- 2015-05-14 DK DK15725195.0T patent/DK3143018T3/da active
- 2015-05-14 TN TN2016000489A patent/TN2016000489A1/en unknown
- 2015-05-14 CR CR20160527A patent/CR20160527A/es unknown
- 2015-05-14 EP EP15725195.0A patent/EP3143018B1/fr active Active
- 2015-05-14 ES ES15725195T patent/ES2874882T3/es active Active
- 2015-05-14 MY MYPI2016704043A patent/MY186598A/en unknown
- 2015-05-14 KR KR1020167034559A patent/KR102534033B1/ko active IP Right Grant
- 2015-05-14 BR BR112016026552-1A patent/BR112016026552B1/pt active IP Right Grant
- 2015-05-14 SI SI201531605T patent/SI3143018T1/sl unknown
- 2015-05-14 HU HUE15725195A patent/HUE054590T2/hu unknown
- 2015-05-14 PT PT157251950T patent/PT3143018T/pt unknown
- 2015-05-14 MX MX2016014939A patent/MX2016014939A/es active IP Right Grant
- 2015-05-14 CN CN201580038353.3A patent/CN106661012B/zh active Active
- 2015-05-14 PL PL15725195T patent/PL3143018T3/pl unknown
- 2015-05-14 PE PE2017000546A patent/PE20171443A1/es unknown
- 2015-05-14 SG SG11201609217UA patent/SG11201609217UA/en unknown
- 2015-05-14 LT LTEP15725195.0T patent/LT3143018T/lt unknown
- 2015-05-14 CU CU2016000166A patent/CU24434B1/es unknown
- 2015-05-14 MA MA39983A patent/MA39983B1/fr unknown
- 2015-05-14 AU AU2015259083A patent/AU2015259083B2/en active Active
- 2015-05-14 EA EA201692300A patent/EA030938B1/ru not_active IP Right Cessation
- 2015-05-14 AR ARP150101498A patent/AR100440A1/es active IP Right Grant
- 2015-05-14 JO JOP/2015/0119A patent/JO3610B1/ar active
-
2016
- 2016-06-16 US US15/184,730 patent/US10195181B2/en active Active
- 2016-11-06 IL IL248785A patent/IL248785B/en active IP Right Grant
- 2016-11-07 ZA ZA2016/07658A patent/ZA201607658B/en unknown
- 2016-11-09 CL CL2016002839A patent/CL2016002839A1/es unknown
- 2016-11-11 PH PH12016502246A patent/PH12016502246A1/en unknown
- 2016-11-11 SV SV2016005313A patent/SV2016005313A/es unknown
-
2018
- 2018-12-21 US US16/230,033 patent/US20190381011A1/en not_active Abandoned
-
2020
- 2020-05-14 US US16/874,595 patent/US20200268718A1/en not_active Abandoned
- 2020-11-04 US US17/089,064 patent/US11672782B2/en active Active
-
2021
- 2021-05-14 HR HRP20210783TT patent/HRP20210783T1/hr unknown
- 2021-06-04 CY CY20211100488T patent/CY1124251T1/el unknown
-
2023
- 2023-05-16 US US18/317,990 patent/US20230301970A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA39983B1 (fr) | Dérivés de carboxamide | |
MA37834A1 (fr) | Analogues de pyridazine 1,4-disubstituée et procédés de traitement de troubles liés à une déficience en smn | |
MA37477A1 (fr) | Modulateurs des voies du complément et leurs utilisations | |
MX2022012317A (es) | Oxisteroles y metodos de uso de los mismos. | |
GEP20207105B (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors | |
MA46337A (fr) | Composé de pyridine | |
MA42678B1 (fr) | Nouveaux analogues nucléosidiques substitués à cycle aromatique bicyclique 6-6 pour une utilisation en tant qu'inhibiteurs de prmt5 | |
EA201891703A1 (ru) | Соединения бензопиразола и их аналоги | |
MA34837B1 (fr) | Composés indoliques ou analogues de ceux-ci utiles dans le traitement de la dégénérescence maculaire liée à l'âge (dmla) | |
MA35275B1 (fr) | Composés de tétrahydropyridopyridine et tétrahydropyridopyrimidine et utilisation de ceux-ci en tant que modulateurs de récepteur c5a | |
PH12018500061A1 (en) | Oxysterols and methods of use thereof | |
MX2019003143A (es) | Compuesto heterociclico sustituido con alquinilo, su metodo de preparacion y su uso medico. | |
EA201692542A1 (ru) | Индановые и индолиновые производные и их применение в качестве активаторов растворимой гуанилатциклазы | |
MA38330B1 (fr) | Dérivés d'acide phosphonique butanoïque de bisphénol substitués en qualité d'inhibiteurs de nep (endopeptidase neutre) | |
MA38865A1 (fr) | Formulation comprenant un agent hypolipidémiant | |
MA39152A1 (fr) | Cyclopentanes substitués en 1,2 utilisés comme antagonistes du récepteur d'orexine | |
MX2016014946A (es) | Derivados de carboxamida. | |
MX2022000945A (es) | Composicion para incrementar la expresion de pgc-1alfa. | |
NZ746906A (en) | Oxaborole esters and uses thereof | |
MX2020013297A (es) | Compuestos para el tratamiento o la prevencion de enfermedades hepaticas. | |
EA202091481A1 (ru) | Замещенные алкиниленовые соединения в качестве противораковых агентов | |
NZ764463A (en) | Heterocyclic compound and application thereof in medicine | |
MA37872A1 (fr) | Sels de composé benzothiazolone utilisés en tant qu'agoniste de beta-2-adrenoceptor | |
MA38973B1 (fr) | Aminohétéroaryles benzamides en tant qu'inhibiteurs de kinase | |
MA38838B1 (fr) | Dérivés de pipéridinyl-indole et leur utilisation en tant qu'inhibiteurs du facteur b du complément |